Xentria Announces Dr. Mustafa Noor as Chief Medical Officer
Dr. Mustafa Noor brings decades of global industry experience and has a proven track record for developing drugs for rare disease indications in multiple rare cardiovascular and endocrine diseases.
Chicago, IL., May. 20, 2021 – Xentria, Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, today announced that Dr. Mustafa Noor has joined the company as its first Chief Medical Officer (CMO). Dr. Noor will be a key member of the executive team which sets the overall strategic direction of the product portfolio. In addition, he will lead the medical, clinical and regulatory functions in support of the Company’s Investigational New Drug (IND) application for XTMAB-16 in the treatment of Sarcoidosis as well as guide development of other therapeutics in the pipeline.
“We are pleased to have Dr. Noor join our leadership team as we continue to progress our promising IND application for XTMAB-16 in the treatment of Sarcoidosis to address unmet needs in global health. Dr. Noor’s experience in rare diseases will be valuable during this pivotal time at the Company,” said Thomas Shea, President at Xentria.”
Dr. Noor is a physician-scientist with medical training at top 10 U.S. institutions, including University of Chicago and UCSF. His experience includes pre-IND preparation and consultation, multiple IND filings, and strategy and design of Phase 2/3 clinical studies. Most recently Dr. Noor was Chief Development Officer at Akcea Therapeutics in Cambridge, MA and responsible for the integrated activities of clinical development overseeing a portfolio of antisense oligonucleotides for rare cardiometabolic diseases. Prior to that, Dr. Noor was VP and TA head for endocrinology at IPSEN where he oversaw successful submission of rare disease sNDA for lanreotide in neuroendocrine tumors and MAA filing for telotristat (Xermelo) for the rare disease of carcinoid syndrome in the EU as part of a strategic collaboration between IPSEN and Lexicon Pharmaceuticals.
Dr. Noor began his career as medical director with BMS in 2001 where he contributed to clinical development of metabolic, cardiovascular and HIV antiviral programs in positions of increasing responsibility leading market differentiation of Reyataz as a lipid and metabolic friendly HIV therapeutic. He also worked at GSK and at Pfizer where he served as Vice President and Clinical Head for GSK’s Center of Excellence in External Drug Discovery (CEEDD) and for Pfizer’s Centers for Therapeutic Innovation (CTI) focusing on open innovation, translational research and collaboration with biotech and academic partners on a portfolio of multiple programs in early phase trials.
Dr. Noor completed his undergraduate and medical degrees at the University of Chicago and fellowship training in Endocrinology and Metabolism at the University of California, San Francisco (UCSF). He is certified in internal medicine and the subspecialty of endocrinology & metabolism and holds a master’s degree in clinical research from Vanderbilt University School of Medicine.
"I am excited to be joining Xentria and look forward to working with the outstanding leadership team here in progressing the Company's IND application for XTMAB-16 in the treatment of Sarcoidosis as well as other pipeline initiatives, with the goal of addressing critical unmet needs for patients," said Dr. Noor. "There are numerous patients worldwide suffering from rare diseases, and they depend on the efforts of companies like Xentria to bring them much needed treatment options."
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. Symptoms range from asymptomatic to severe—including respiratory insufficiency, blindness, neurological disease, and cardiac death. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
XTMAB-16 is a chimeric human-murine IgG1k anti-TNFa monoclonal antibody with a molecular weight of ~149 kDa being developed as a novel biologic product for the treatment of patients with sarcoidosis with or without extrapulmonary involvement. No TNF-a inhibitor is currently approved for the treatment of sarcoidosis. Extensive analyses have been conducted to demonstrate the physio-chemical properties and pharmacology of XTMAB-16 as a TNF-a inhibitor.
Xentria, whose name stems from the word “centrality” was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious biologics to address critical unmet need for patients suffering from rare diseases. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development, clinical science, manufacturing, and commercialization and driven to treat the clinical and social burdens of diseases while fostering sustainable growth.
To learn more about Xentria visit www.xentria.com
Source: Xentria Inc.
Thomas Shea, President
224 443 4522